Aura Biosciences
AURAAURA · Stock Price
Historical price data
Overview
Aura Biosciences is developing first-in-class, targeted oncology therapies designed to treat solid tumors with high precision. Its core innovation is the Virus-Like Drug Conjugate (VDC) platform, which utilizes non-infectious virus-like particles to deliver potent cytotoxic agents directly to cancer cells. The company's lead program is in Phase 2 development for choroidal melanoma, a significant unmet need, with a strategic pipeline expansion planned into urologic and other solid tumors. Aura's mission is to create a new standard of care that improves patient outcomes by sparing healthy tissue.
Technology Platform
Proprietary Virus-Like Drug Conjugate (VDC) platform that uses non-infectious virus-like particles to target heparan sulfate proteoglycans on cancer cells for the precise delivery of cytotoxic payloads or nucleic acids.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Bel-sar | Choroidal Melanoma | Phase 3 | |
| AU-011 | Eye Cancer | Phase 2 | |
| AU-011 | Uveal Melanoma | Phase 2 | |
| Light-activated AU-011 | Uveal Melanoma | Phase 1/2 | |
| AU-011 | Non-muscle-invasive Bladder Cancer | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
In choroidal melanoma, Aura faces competition from the entrenched standard of care (radiotherapy/surgery) rather than direct pharmaceutical competitors. For broader solid tumors, the VDC platform will need to differentiate itself within the crowded field of targeted therapies, including antibody-drug conjugates and other novel conjugates.